Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05211102
Other study ID # Venous sinus thrombosis
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date June 1, 2023

Study information

Verified date January 2022
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cerebral venous sinus thrombosis (cvst) is an underdiagnosed neurological condition with variable clinical presentations and variable risk factors CVST is often an underdiagnosed cause of acute or slowly progressive neurological deficit. With increasing awareness of the entity and easy accessibility to the non-invasive test like CT and MRI scans,CVST cases are now being diagnosed more frequently and it is now thought to occur more commonly than previously assumed.it is also probably true that this condition is more frequent in underdeveloped countries


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date June 1, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. All patients admitted to the neurology department and ER of an assuit university hospital with the diagnosis of venous sinus thrombosis 2. accepting to participate in the study 3. of both sex above 18 years and below 70 years Exclusion Criteria: - 1. any case evident to have neurological deficit due to cause other than venous sinus thrombosis 2. patients refused to participate in this study 3-patients with uncertainty about her imaging study

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary cerebral venous sinus thrombosis Clinical presentations of cerebral venous sinus thrombosis 1 year
See also
  Status Clinical Trial Phase
Completed NCT04569279 - Rivaroxaban vs. Warfarin in CVT Treatment Phase 3
Recruiting NCT03778502 - DOAC in Unusual Site Venous Thrombosis
Completed NCT02585713 - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Phase 3
Active, not recruiting NCT03329365 - Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
Active, not recruiting NCT03080883 - Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Phase 3
Recruiting NCT05021198 - The Norwegian Cerebral Venous Thrombosis Study
Completed NCT05448248 - Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)